BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1452 related articles for article (PubMed ID: 22842585)

  • 1. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
    Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil.
    Park JH; Park YS; Koh HC
    Toxicol Lett; 2016 Sep; 258():36-45. PubMed ID: 27313094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
    Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
    J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
    Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
    Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
    Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
    Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
    Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
    Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.
    Mu X; He G; Cheng Y; Li X; Xu B; Du G
    Pharmacol Biochem Behav; 2009 Jun; 92(4):642-8. PubMed ID: 19327378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.